The company continues to build evidence for the added sensitivity offered by its urine- and blood-based liquid biopsy approach in an effort to engage clinicians.
The collaboration will develop a clinical framework for deploying the Trovera liquid biopsy tests and general best practices for urine-based liquid biopsies.
The partnership will utilize Trovagene's KRAS ctDNA test to try to detect pancreatic cancer and monitor patients' responses to therapy.
The company's quarterly revenues of $120,000 fell significantly short of the $260,000 expected by analysts on average.
The firm said the two executives failed to present a lucrative corporate opportunity to Trovagene and took it for their own personal benefit instead.
Despite the gains it recorded for revenues in the quarter and the full year, the firm missed analyst estimates for both revenues and net loss for Q4 and 2015.
The firm's circulating tumor DNA tests and services will now be available through FedMed clients such as insurance giants Aetna, Cigna, and Humana.
With the agreement, Trovagene's circulating tumor DNA Precision Cancer Monitoring tests and services will be available in-network to 22 million individuals.
The decrease in net loss was primarily due to changes in the fair market value derivative instruments during Q3 2015 compared to the year-ago period.
The investment bank noted Trovagene's use of urine as a biofluid for its liquid biopsy tests and gave the firm a $10 price target on its stock.
According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.
US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.
An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.